Zydus Cadila Healthcare Ltd.

Gujrat, India

Zydus Cadila Healthcare Ltd.

Gujrat, India
SEARCH FILTERS
Time filter
Source Type

Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Albany, NY, May 21, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027 Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives. The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines. Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA. In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities. Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.html The pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Albany, NY, May 21, 2017 --( PR.com )-- Tetanus is a frightening disease that has plagued mankind since ancient times. Market Research Hub (MRH) has recently broadcasted a pipeline study done on this bacterial disease and titled as “Tetanus - Pipeline Review, H1 2017.” This study examines comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Moreover, its pipeline analysis by companies involved in its therapeutic development is also mentioned in detail.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives.The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines.Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA.In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities.Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.htmlThe pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


Shakeel F.,King Saud University | Shafiq S.,Zydus Cadila Healthcare Ltd. | Haq N.,King Saud University | Alanazi F.K.,King Saud University | Alsarra I.A.,King Saud University
Expert Opinion on Drug Delivery | Year: 2012

Introduction: In recent years, nanoemulsions have been investigated as potential drug delivery vehicles for transdermal and dermal delivery of many compounds especially hydrophobic compounds in order to avoid clinical adverse effects associated with oral delivery of the same compounds. Droplet size and surface properties of nanoemulsions play an important role in the biological behavior of the formulation. Areas covered: In this review, current literature of transdermal and dermal delivery of hydrophobic compounds both in vitro as well as in vivo has been summarized and analyzed. Expert opinion: Nanoemulsions have been formulated using a variety of pharmaceutically acceptable excipients. In many cases of dermal and transdermal nanoemulsions, the skin irritation or skin toxicity issues on human beings have not been considered which needs to be evaluated properly. In the last decade, much attention has been made in exploring new types of nanoemulsion-based drug delivery system for dermal and transdermal delivery of many hydrophobic compounds. This area of research would be very advantageous for formulation scientists in order to develop some nanoemulsion-based formulations for their commercial exploitation and clinical applications. © 2012 Informa UK, Ltd.


Selva Kumar P.,SunRise University | Selva Kumar P.,Syngene International Ltd | Pandiyan K.,Syngene International Ltd | Rajagopal K.,SunRise University | Rajagopal K.,Zydus Cadila Health Care Ltd
International Journal of Pharmacy and Pharmaceutical Sciences | Year: 2014

Objective: A simple, rapid, accurate, linear, precise, specific, robust, rugged and stability indicating high performance liquid chromatography (HPLC) method has been developed for estimation of Ivabradine hydrochloride from solid oral dosage form. Methods: The chromatographic separation was obtained using a mobile phase composition at a ratio of 50:50 (v/v) of 10 mM ammonium acetate buffer pH 6.0 and methanol on Phenomenex Kinetex C18 column (150 × 4.6 mm, 5 μm), ambient temperature with UV detection at 285 nm at a flow rate of 1.0 ml/minute. The retention was at 3.1 mins. Results: The stability indicating capability of the method was proven by subjecting the drug to stress conditions as per ICH recommended test conditions such as acid and alkali hydrolysis, oxidation, photolysis, thermal and humidity degradation. The peak purity plots show that the Ivabradine hydrochloride peak is homogeneous and that there are no co eluting peaks indicating that the method is stability indicating and specific. The % RSD value was 0.48% for method precision. Ruggedness of the method is indicated by the overall RSD values of 0.52 % for Ivabradine hydrochloride. The linearity of response for Ivabradine hydrochloride was determined over the range 70.69 to 131.29 μg/ml with correlation coefficient of 0.99974. The mean accuracy of triplicate samples of three different levels was found at 99.03% with %RSD of 0.38%. Conclusion: The analytical method validation data showed excellent results for precision, linearity, specificity, accuracy, ruggedness and robustness. The present method can be successfully used for routine quality control and stability studies. This method can also used for LCMS analysis as mobile phase is LCMS compatible.


Patil V.,P.A. College | Patel N.,Zydus Cadila Healthcare Ltd. | Patel N.,P.A. College
Journal of Pharmaceutical Negative Results | Year: 2011

Objective: The objective of the present study was to investigate the antimicrobial activity of seed of Santalum album Linn. (Family: Santalaceae) in various microbial strains. Materials and Methods: The effects of ethanolic extract of seed of S. album were analyzed in different microorganisms at a concentration of 5 mg/ml per disk. Results: The result indicated that the ethanolic extract of seed of S. album did not show any zone of inhibition against the tested microorganisms. Conclusion: The ethanolic extract of seed of S. album has no significant antimicrobial activity.


Nathani B.R.,P.A. College | Pandya K.S.,P.A. College | Jeni M.M.,P.A. College | Prasad A.,Zydus Cadila Healthcare Ltd
Journal of Chemical and Pharmaceutical Research | Year: 2011

Some new N-[3-(2-oxo-1, 2-dihydro-indol-3-ylidene-hydrazinocarbonyl) benzyl] benzamide (III) have been synthesised from different isatin derivatives (I) by condensing with N-[3- (Hydrazinocarbonyl) benzyl] benzamide (II). Their chemical structures have been confirmed by IR, 1H NMR, Mass and by elemental analysis. Investigation of antimicrobial activity of compounds was done by the disk diffusion technique. Among the compounds tested, the compound with 5-Cl, 5-I substitution showed the most favourable antimicrobial activity.


Patel M.M.,Sudan University of Science and Technology | Bhuva S.D.,Veeda Clinical Research | Patel M.M.,Zydus Cadila Healthcare Ltd
Reviews in Analytical Chemistry | Year: 2015

An extensive survey of the literature published in various analytical and pharmaceutical chemistry-related journals have been conducted, and the instrumental analytical methods that were developed and used for the determination of proton pump inhibitors in bulk drugs, formulations, and biological fluids have been reviewed. This review covers the time period from 1990 to 2011 during which 80 analytical methods, including all types of spectrophotometric and chromatographic techniques were reported. High-performance liquid chromatography (HPLC) with ultra violet (UV) detection was found to be the technique of choice for many workers, and more than 50 methods were based on liquid chromatography (LC) and ultra violet (UV). A critical analysis of the reported data was carried out and the present state of the art of the analytical techniques for the determination of omeprazole, esomeprazole, pantoprazole, rabeprazole, dexrabeprazole, tenatoprazole, lansoprazole, and dexlansoprazole is discussed. © 2015 by De Gruyter.


Shafiq S.,Zydus Cadila Healthcare Ltd. | Shakeel F.,University of Benghazi
Clinical Research and Regulatory Affairs | Year: 2010

The aim of the present investigations was to evaluate the capacity of a combination of Labrasol and Plurol oleique as surfactant and cosurfactant on self-nanoemulsification efficiency of ramipril nanoemulsion. Sefsol-218, Labrasol, Plurol oleique, and standard buffer solution (pH 5.0) were selected as oil phase, surfactant, cosurfactant, and aqueous phase, respectively. Nanoemulsion formulations of ramipril were developed by a spontaneous emulsification method. Pseudoternary phase diagrams were constructed to identify nanoemulsion zones of ramipril. Selected formulations were evaluated in terms of thermodynamic stability tests using centrifugation, heating-cooling cycles, and freeze-thaw stress test. Some formulations were found stable and other formulations were unstable upon thermodynamic stability tests. Thermodynamically stable formulations were taken for self-nanoemulsification efficiency test. All the selected formulations passed self-nanoemulsification test in grade E only but not in grades A and B. Because none of the formulations passed the self-nanoemulsification efficiency test in grades A and B, it was concluded that a combination of Labrasol and Plurol is not suitable as surfactant and cosurfactant, respectively, for oral or self-nanoemulsifying drug delivery system of ramipril. © 2010 Informa UK Ltd.


Nathani B.R.,P.A. College | Pandya K.S.,P.A. College | Jeni M.M.,P.A. College | Patel M.R.,Zydus Cadila Healthcare ltd
Der Pharma Chemica | Year: 2011

Some new N-[3-(2-Oxo-1, 2-dihydro-indol-3-ylidene-hydrazinocarbonyl)-benzyl]-nicotinamide (III) have been synthesised from different isatin derivatives (I) by condensing with N-(3-hydrazinocarbonylbenzyl) nicotinamide (II). Their chemical structures have been confirmed by IR, 1H NMR, Mass and by elemental analysis. Investigation of antimicrobial activity of compounds was done by the disk diffusion technique. Among the compounds tested, the compound with 5-F, 5-CH3 substitution showed the most favourable antimicrobial activity.


Maitreyi Z.,Institute of Pharmaceutical Education and Research | Amit K.,Zydus Cadila Healthcare Ltd
International Journal of Advances in Pharmaceutical Sciences | Year: 2010

The reverse phase high performance liquid chromatography (RP-HPLC) method of Atenolol and Hydrochlorothiazide is individually available in United State of Pharmacopoeia-27 (USP-27) but no reference is available for combined estimation of Atenolol and Hydrochlorothiazide in tablets formulation. The aim of our present work was to develop a precise and validated RP-HPLC method for the simultaneous determination of Atenolol and Hydrochlorothiazide in tablets formulation. The quantification was carried out by using Zorbax SB-CN (250 x 4.6 mm), 5μm column in isocratic mode with mobile phase, Water: Buffer: Methanol (50:35:15). The flow rate was 1.2 ml/min. The peak purity of Atenolol and Hydrochlorothiazide were 0.999 and 1.000 respectively. Ruggedness and robustness of method were performed and the percentage relative standard deviation (RSD) was found below 2.0%. The percentage recovery was found in the range of 98% to 102% at three different levels. Calibration curves were linear over studies ranges with correlation co-efficient found between the range of 0.99 to 1.00. Sample and standard solution stability study was performed over 21 h at room temperature and found stable. The percentage deviation was below 2.0%.


Zaveri M.,Institute of Pharmaceutical Education and Research | Khandhar A.,Zydus Cadila Healthcare Ltd
International Journal of Advances in Pharmaceutical Sciences | Year: 2010

The objective of this present work was to develop and validate analytical method for quantitative determination of Paracetamol and Etoricoxib in a tablet formulation and also the comparison of invitro data with reference dosage form. Chromatographic separations of the two drugs were analyzed on a Kromasil C18 column (25cm × 4.6mm, 5μm). The mobile phase constituted of Buffer: Acetonitirile with gradient program was delivered at the flow rate 1.0 mL/min. Detection was performed at 220 nm. Separation was completed within 20 min. Calibration curves were linear with coefficient correlation between 0.99 to 1.0 over a concentration range of 48 to 146 μg/mL of Paracetamol and 6 to 19 μg/mL for Etoricoxib respectively. The relative standard deviation (R.S.D) was found to be less than 2.0%. Analysis for dissolution study was also performed by Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) method. Difference factor (f1) were found to be 2.85 and 3.83 and similarity factor (f2) were found to be 73.514 and 68.961 for Paracetamol and Etoricoxib respectively. © arjournals.org, All rights reserved.

Loading Zydus Cadila Healthcare Ltd. collaborators
Loading Zydus Cadila Healthcare Ltd. collaborators